A voluntary preventative product recall of Cilest® 250/35 Oral Contraceptive Tablets (250μg norgestimate 35μg ethinyl estradiol) is being initiated by Janssen-Cilag International N.V.

The recall is due to a reported slower than expected solubility of an active ingredient whcih can potentially lead to decreased contraceptive effect.

It has been reported that the likelihood of patients experiencing an adverse event due to this appears to be very low.

Stock of Cilest® will be withdrawn from pharmacies.

Patients are requested to contact their doctor to be advised regarding the continuation of their treatment.

More information can be obtained on 2343 9000.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.